New Insights into the Pathogenesis of Coagulation Dysfunction in Acute Promyelocytic Leukemia

References

• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukemias. Br. J. Haematol. 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. A variant form of hypergranular proniyelocytic leukemia. Ann. Intern. Med. 1980; 92: 261–280
   PubMed Web of Science ®Google Scholar
• Hillestad L. K. Acute promyelocytic leukemia. Acta. Med. Scmd. 1957; 159: 189–194
   PubMed Web of Science ®Google Scholar
• Larson R. A., Kondo K., Vardiman J. M., Butler A. E., Golomb H. M., Rowley I. D. Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 1984; 76: 827–841
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., McCredie K. B., Beran M., Walters R., Dalton W. T., Hittleman W., Freir-Eich E. J. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J. Clin. Oncol. 1985; 3: 793–798
   PubMed Web of Science ®Google Scholar
• Stone R. M., Maguire M., Goldberg M. A., Antin J. W., Rosenthal D. S., Mayer R. J. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: Experience in 34 patients. Blood 1988; 71: 690–696
   PubMed Web of Science ®Google Scholar
• Baker W., Bang N. U., Nachman R. L., Raafat R. T., Honvitz H. I. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. Ann. Intern. Med. 1964; 61: 116
   PubMed Web of Science ®Google Scholar
• Rand J. J., Maloney W. D., Sise H. S. Coagulation defects in acute promyelocytic leukemia. Arch. Int. Med. 1969; 123: 39–47
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Sultan C. Acute promyelocytic leukemia: haemorrhagic manifestations and morphologic criteria. Br. J. Haematol. 1975; 29: 373–376
   PubMed Web of Science ®Google Scholar
• Groopman J., Ellman L. Acute promyelocytic leukemia. Am. J. Hematol. 1979; 7: 395–408
   PubMed Web of Science ®Google Scholar
• Jones M. E., Saleem A. Acute promyelocytic leukemia. A review of the literature. Am. J. Med. 1978; 65: 673–677
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Rowley J. D., Vardiman J. W., Testa J. R., Butler A. Microgranular acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cyto-genetic entity. Blood 1980; 55: 253–259
   PubMed Web of Science ®Google Scholar
• Mertelsman R., Thaler H. T., To L., Gee T. S., Mc-Kenzie S., Schauer P., Pridman A., Arlin Z., Cirrin-Cione C., Clarkson B. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773–781
   PubMed Web of Science ®Google Scholar
• Collins A. J., Bloomfield C. D., Peterson B. A., Mc-Kenna R. W., Edson R. Acute promyelocytic leukemia: Management of the coagulopathy during dauno-rubicin-prednisone remission induction. Arch. Int. Med. 1978; 138: 1677–1680
   PubMed Web of Science ®Google Scholar
• Bernard J., Weil M., Boiron M., Jacquillat C., Flandrin G., Gemon M. F. Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood. 1973; 41: 489–496
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T. S., Reich L. M., Kempin S. J., Naval A. N., Clarkson B. D. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood., 73: 1116–1122
   PubMed Web of Science ®Google Scholar
• Fenaux P., Pollet J. P., Vandenbossche-Simon L., Morel P., Zandecki M., Jouet J. P., Bauters F. Treatment of acute promyelocytic leukemia: A report of 70 cases. Leuk. Lymph. 1991; 4: 239–248
   PubMed Web of Science ®Google Scholar
• Kingsley E. C., Dune B. G. M., Gurewell H. S. Acute promyelocytic leukemia. Wesr. J. Med. 1987; 140: 322–327
   Google Scholar
• Arlin Z., Kenipin S., Mertelsman R. T., Gee T., Hig-Gins C., Jhanwar S., Chaganti R. S. K., Clarkson B. Primary therapy of acute promyelocytic leukemia: Results of amsacrine- and daunorubicin-based therapy. Blood 1984; 63: 211–212
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Estey E. H., McCredie K. B., Smith T. L., Dalton W. T., Cork A., Trujillo J. M., Freireich E. J. Acute promyelocytic leukemia: The MD Anderson Hospital experience. Am. J. Med. 1986; 80: 789–794
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Bagley J., Abrell E. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. Am. J. Med. 1972; 52: 167–174
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Kwann H. C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543–553
   PubMed Web of Science ®Google Scholar
• Avvisati G., Ten Cate J. W., Sturk A., Lamping R., Petti M. C., Mandelli F. Acquired alpha 2 antiplas-min deficiency in acute promyelocytic leukemia. Er. Haematol. 1988; 70: 43–48
   PubMed Web of Science ®Google Scholar
• Nykkertz S. Fibrinolysis: an overview. Sem. Thromb. Hemost. 1984; 10: 1–5
   PubMed Web of Science ®Google Scholar
• Collen D. On the regulation and control of fibrinolysis. Thromb. Haemost. 1980; 43: 77–89
   PubMed Web of Science ®Google Scholar
• Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–387
   PubMed Web of Science ®Google Scholar
• Astedt B., Wallen P., Aasted B. Occurrence of both urokinase and tissue plasminogen activator in human seminal plasma. Thromb. Res. 1979; 16: 463–472
   PubMed Web of Science ®Google Scholar
• Wilson E. L., Becker M. L., Hoal E. G., Dowdle E. B. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res. 1980; 40: 933–938
   PubMed Web of Science ®Google Scholar
• Dan K., Andreasen P. A., Grondahl-Hansen J., Kristen-Sen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer. Res. 1985; 44: 139–266
   PubMed Web of Science ®Google Scholar
• Gurewich V., Pannell R., Louie S., Kelley P., Suddith R. L., Greenlee R. Effective and fibrin-specific clot lysis by a rymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J. Clin. Invest. 1984; 73: 1731
   PubMed Web of Science ®Google Scholar
• Wun T. C., Schleuning W. D., Reich E. Isolation and characterization of urokinase from human plasma. J. Bio. Chem. 1982; 257: 3276–3283
   PubMed Web of Science ®Google Scholar
• Andreasen P. A., Neilsen L. S., Kristensen P., Grondahl-Hansen J., Skriver L., Dano K. Plaminogen activator inhibitor from human fibrosarcoma cells binds uro-kinase-type plasminogen activator behind its proenzyme. J. Bio. Chem. 1986; 761: 7644–7651
   Google Scholar
• Presta M., Moscatelli D., Joseph-Silverstein J., Rif-Kin D. B. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production DNA-synthesis and migration. Mol. Cell Bio. 1986; 6: 4060–4066
   PubMed Web of Science ®Google Scholar
• Kawano T., Morinioto K., Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J. Biochem. 1970; 67: 333–342
   PubMed Web of Science ®Google Scholar
• Astedt B., Lecander I., Brodin T., Lundblad A., Low K. Purification of a specific plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasniinogen activator. Thromb. Haemost. 1985; 53: 122–125
   PubMed Web of Science ®Google Scholar
• Saksela O., Hovi T., Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte/macrophages. J. Cell Physiol. 1985; 122: 125–132
   PubMed Web of Science ®Google Scholar
• Vassalli J. I., Dayer J. M., Wohlwend A., Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytesniacrophages. J. Exp, Med. 1984; 159: 1653–1668
   PubMed Web of Science ®Google Scholar
• Golder J. P., Stephens R. W. Minactivin: a human inonocyte product which specifically inactivates uro-kinase-type plasminogen activators. Eur. J. Riochem._I 1983; 136: 517–522
   PubMed Web of Science ®Google Scholar
• Ye R. D., Wun T. C., Sadler J. E. cDNA cloning and expression in Eschericha coli of a plasminogen activator inhibitor from human placenta. J. Bio. Chem. 1987; 262: 3718–3725
   PubMed Web of Science ®Google Scholar
• Kruithof E. K., Vassalli J. D., Schleuning W. D., Mat-Taliano R. J., Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J. Bio. Chem. 1986; 261: 11207–11213
   PubMedGoogle Scholar
• Gentor C., Kruithof E. K., Schleuning W. D. Phorbol ester includes the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase type plasminogen activator in human U-937 lymphoma cells. J. Cell Bio. 1987; 104: 705–712
   PubMed Web of Science ®Google Scholar
• Belin D., Wohlwend A., Schleuning W. D., Kruithof E. K., Vassalli J. D. Facultative polypeptide trans-location allows a single MRNA to encode the secreted and cystolic forms of plasminogen activator inhibitor 2. EMBOJ. 1989; 8: 3287–3294
   PubMed Web of Science ®Google Scholar
• Kwaan H. C. The Plasminogen-plasmin system in malignancy. Cancer and Metastasis Reviews 11. Kluwer Academic Publishers, LancasterUK 1992; 291–311
   Google Scholar
• Wigler M., Weinstein I. B. Tumor promoter induces plasminogen activator. Nature 1979; 259: 232–233
   Web of Science ®Google Scholar
• Wilson E. L., Reich E. Plasminogen activator in chick fibroblasts: Induction of synthesis by retinoic acid, synergism with viral transformation and phorbol ester. Cell 1978; 15: 385–392
   PubMed Web of Science ®Google Scholar
• Ritkin D. B. Plasminogen activator synthesis by cultured human embryonic lung cells: characterization of the suppressive effect of corticosteroids. J. Cell Physiol. 1978; 97: 421–428
   PubMed Web of Science ®Google Scholar
• Gross J. L., Krupp M. N., Ritkin D. B., Lane M. D. Down-regulation of epidermal growth factor receptor correlated with plasminogen activator activity in hunian A43I epidermoid carcinoma cells. Proc. Natl. Acad. Sci. USA 1983; 80: 2276–2280
   PubMed Web of Science ®Google Scholar
• Chan T. K., Chan G. T., Chan V. Hyprofi-brinogenemia due to increased fibrinolysis in two patients with acute promyelocytic leukemia. Aust. NZ J. Med. 1984; 14: 245–249
   PubMedGoogle Scholar
• Kahle L. H., Avvisati G., Lampling R. J., Moretti T., Mandelli F., Ten Cate J. W. Turnover of alpha-2 antiplasmin in patients with acute promyelocytic leukemia. Scand. J. Clin. Lab. Invest. 1985; 45(Suppl 178)75–80
   Google Scholar
• Ogaton D., McAndrew G. M., Ogston C. M. Fibrinolysis in leukemia. J. Clin. Pathol. 1968; 21: 136–139
   PubMed Web of Science ®Google Scholar
• Schwartz B. S., Williams E. C., Conlan M. G., Mosher D. F. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2–plasmin inhibitor deficiency. Ann. Int. Med. 1986; 105: 873–877
   PubMed Web of Science ®Google Scholar
• Velasco F., Torres A., Andres P., Martinez F., Gomez P. Changes in plasma levels of pro-lease and fibrinolytic inhibitors induced by treatment of acute myeloid leukemia. Thromb. Haemost. 1984; 52: 81–84
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Abrell E. Studies of the pro-coagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br. J. Haematol. 1973; 24: 89–99
   PubMed Web of Science ®Google Scholar
• Brower M. S., Harpel P. C. Proteolytic cleavage and inactivation of alpha-2–plasmin inhibitor and CI in-activator by human polymorphonuclear leukocyte elastase. J. Bio. Chem. 1982; 257: 9840–9854
   PubMedGoogle Scholar
• Wilson E. L., Jacobs P., Dowdle E. B. The secretion of plasminogen activators by human myeloid leu-kemic cells in vitro. Blood 1983; 61: 568–574
   PubMed Web of Science ®Google Scholar
• Frances R. B., Jr., Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravas-cular coagulation: clinicopathologic correlations. J. Lab. Clin. Med. 1987; 110: 541–547
   PubMedGoogle Scholar
• Wilson E. L., Francis C. E. Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human haemopoietic cells. J. Exp. Med. 1987; 165: 1609–1623
   PubMed Web of Science ®Google Scholar
• Alving B. M., Krishnamurti C., Liu Y. P., Lucas D. L., Wright D. G. Stimulated production of urokinase by plasminogen activator inhibitor 2 by the human promyelocytic leukemia cell line HL-60. Thromb. Res. 1988; 51: 175–185
   PubMed Web of Science ®Google Scholar
• Pike C. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 1991; 138: 1059–1067
   PubMed Web of Science ®Google Scholar
• Hoosein N. M. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 1991; 3: 255–264
   PubMedGoogle Scholar
• Kwaan H. C., Keer H. N. Fibrinolysis and cancer. Sem. Thromb. Hemost. 1990; 16: 230–235
   PubMed Web of Science ®Google Scholar
• Vassalli J. D., Sappino A. P., Belin D. The plasminogen activator/plasmin system. J. Clin. Invest. 1991; 88: 1067–1072
   PubMed Web of Science ®Google Scholar
• Kwann H. C., Keer H. N., Radosevich J. A., Cajot J. F., Ernst R. Components of the plasminogen-plasmin system in human tumor cell lines. Sem. Thromb. Hemost. 1991; 17: 175–182
   PubMed Web of Science ®Google Scholar
• Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1–8
   PubMed Web of Science ®Google Scholar
• Bach R. R. Initiation of coagulation by tissue factor. Crit. Rev. Biochem. 1988; 23: 339–368
   PubMed Web of Science ®Google Scholar
• Edgington T. S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb. Haemost. 1991; 66: 67–79
   PubMed Web of Science ®Google Scholar
• McGee M. P., Devlin R., Saluta G., Koren H. Tissue factor and factor VII messenger RNAs in human alveolar macrophages: effects of breathing ozone. Blood. 1990; 75: 122–127
   PubMed Web of Science ®Google Scholar
• Hancock W. W., Rickles F. R., Ewan V. A., Atkins R. C. Immunohistological studies with Al-3, a monoclonal antibody to activated human monocytes and macrophages. J. Immunol. 1986; 136: 2416–2420
   PubMed Web of Science ®Google Scholar
• Ewan V. A., Cieplinski W., Hancock W. W., Gold-Schneider I., Boyd A. W., Rickles F. R. Production and characterization of a monoclonal antibody (Al-3) that binds selectively to activated monocytes and inhibits monocyte procoagulant activity. J. Immunol. 1986; 136: 2408–2415
   PubMed Web of Science ®Google Scholar
• Morrissey J. H., Fair D. S., Edgington T. S. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb. Res. 1988; 52: 247–261
   PubMed Web of Science ®Google Scholar
• Schwartz B. S., Bradshaw J. D. Differential regulation of tissue factor and plasminogen activator inhibitor by human mononuclear cells. Blood. 1989; 74: 1644–1650
   PubMed Web of Science ®Google Scholar
• Gregory S. A., Morrissey J. H., Edgington T. S. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol. Cell Bio. 1989; 9: 2752–2755
   PubMed Web of Science ®Google Scholar
• Jackson C. M., Nemerson Y. Blood Coagulation. Ann. Rev. Biochem. 1980; 49: 765–811
   PubMed Web of Science ®Google Scholar
• Nagy J. A., Brown L. F., Senger D. R., Lanir N., Van De Water L., Dvorak A. M., Dvorak H. F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta. 1988; 948: 305–326
   Web of Science ®Google Scholar
• Rickles F. R., Edwards R. L. Leukocytes and tumor cells in thrombosis. Hemostasis and Thrombosis3rd Edition, R. W. Colman, J. Hirsch, V. J. Mar-Der, E. W. Salzman. JB Lippincott Co., Philadelphia, PA 1993, in press
   Google Scholar
• Rivers R. P., Hathway W. E., Weston W. L. The endotoxin-induced coagulant activity of human monocytes. Br. J. Haematol. 1975; 30: 311–316
   PubMed Web of Science ®Google Scholar
• Edwards R. L., Rickles F. R., Bobrove A. M. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359–370
   PubMed Web of Science ®Google Scholar
• Gregory S. A., Kornbluth R. S., Helin H., Remold H. G., Edgington B. Monocyte procoagulant inducing factor: a lymphokine involved in the T cell-instructed monocyte procoagulant response to antigen. J. Immunol. 1986; 137: 3231–3239
   PubMed Web of Science ®Google Scholar
• Faucette K. J., Parker C. J., McCluskey T., Bernshaw N. J., Rodgers G. M. Induction of tissue factor activity in endothelial cells and monocytes by a modified form of albumin present in normal human plasma. Blood. 1992; 79: 2288–2895
   PubMedGoogle Scholar
• Niemetz J., Fani K. Role of leukocytes in blood coagulation and the generalized Schwartzman reaction. Nature 1971; 232: 247–248
   PubMed Web of Science ®Google Scholar
• Starzl T. E., Boehmig H. J., Amemiya H., Wilson C. B., Dixon F. J., Giles G. R., Simpson K. M., Hal-Grimson C. G. Clotting changes, including disseminated intravascular coagulation during rapid renal-homo-graft rejection. N. Engl. J. Med. 1970; 283: 283–390
   Google Scholar
• Hancock W. W., Gee D., Demoerloose P., Rickles F. R., Ewan V. A., Atkins R. C. Immunohisto-chemical analysis of serial biopsies taken during human renal allograft rejection: changing profile of infiltrating cells activation of the coagulation system. Transplant 1985; 39: 430–438
   PubMed Web of Science ®Google Scholar
• Andoh K., Sadakata H., Uchiyama T., Narahara N., Tanaka H., Kobayashi N., Maekawa T. One-stage method for assay of tissue factor activity of leukemic cell with special reference to disseminated intravascular coagulation. Am. J. Clin. Pathol. 1990; 93: 679–684
   PubMed Web of Science ®Google Scholar
• Kubota T., Andoh T., Sadakata H., Tanaka H., Kobayashi N. Tissue factor released from leukemic cells. Thromb. Haemost. 1991; 65: 59–63
   PubMed Web of Science ®Google Scholar
• Eiseman G., Stefanini M. Thromboplastic activity of leukemic white cells. Proc. Soc. Exp. Bio. Med. 1954; 86: 763–765
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Abrell E. Studies or procoagulant and fibrinolytic activity of promyelocytes in acute pro-myelocytic leukemia. Br. J. Haematol. 1973; 24: 89–99
   PubMed Web of Science ®Google Scholar
• Gouault-Heilmann M., Chardon E., Sultan C., Josse F. The procoagulant factor of leukemic promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor. Br. J. Haematol. 1975; 30: 151–158
   PubMed Web of Science ®Google Scholar
• Bauer K. A., Conway E. M., Bach R., Konigsberg W. H., Griffin I. D., Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Thromb. Res. 1989; 56: 425–430
   PubMed Web of Science ®Google Scholar
• Von Melchner H., Hoffken K. Human placental conditioned medium reverses apparent committment to differentiation of human promyelocytic leukemia cells (HL-60). Blood 1985; 66: 1469–1472
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Hair G. A., Schneizel M., Tallman M. S., Lanotte M., Kwaan H. Downregulation of the tissue factor gene in the human progranulocytic leukemic cell line NB4 in response to all-trans retinoic acid: Possible mechanism for the amelioration of the thrombohemorrhagic complications of APL. Thromb Hemo Suppl (Abstr) 1993, In press
   Google Scholar
• Hair G. A., De Moerloose P. A., Lopez A., Ewan V. A., Boyd A. W., Burns G. F., Triglia T. T., Vadas M. A., Burgess A. W., Rickles F. R., et al. Expression of tissue factor in human blood cells: Discordant procoagulant activity, tissue factor-related antigen and tissue factor mRNA content, Submitted for publication
   Google Scholar
• Falanga A., Gordon S. G. Isolation and characterization of cancer procoagulant A: A cysteine protease from malignant tissue. Biochem. 1985; 24: 5558–5567
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Miliani A., Carossino A. M., Giordiani R., Cinotti S., Filimberti E., Saccardi R., Ber-Nabei P., Guidi G., Diguglielmo R., Pistoia V., Ferrar-Ini M., Nawroth P. P., Stem D. Potential role of interleukin-l as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am. J. Med. 1988; 84: 240–250
   PubMed Web of Science ®Google Scholar
• Gordon S. G., Franks J. J., Lewis B. Cancer procoagulant A: A factor X-activating procoagulant from malignant tissue. Thromb. Res. 1975; 6: 127–137
   PubMed Web of Science ®Google Scholar
• Donati M. B., Gambacorti-Passerin C., Casali B., Falanga A., Vannotti P., Fossati G., Semeraro N., Gordon S. G. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986; 46: 6471–6474
   PubMed Web of Science ®Google Scholar
• Gordon S. G., Hasiba U., Poole M. A., Cross B. A., Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261–1265
   PubMed Web of Science ®Google Scholar
• Brown M., Kiehn D. Protease effects on specific growth properties of normal and transformed baby hamster kidney cells. Proc. Nart. Acad. Sci. USA 1977; 74: 2874–2878
   PubMed Web of Science ®Google Scholar
• Falanga A., Alessio M. G., Donati M. B., Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870–875
   PubMed Web of Science ®Google Scholar
• Francis J. L., El-Baruni K., Roath O. S., Taylor L. Factor X-activating activity in normal and malignant colorectal tissue. Thromb. Res. 1988; 52: 207–217
   PubMed Web of Science ®Google Scholar
• Edwards R. L., Brande W. Procoagulant activity of the VX2 carcinoma: Tissue factor activity is expressed by tumor cells. Clin. Res. 1989; 37: 466A
   Google Scholar
• Bevilacqua M. P., Pober J. S., Majeau G. R., Cotran R. S., Bimhrone M. A., Jr. Interleukin 1 (IL-I) inducing biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 1984; 160: 618–623
   PubMed Web of Science ®Google Scholar
• Nawroth P. P., Handley D., Esmon C. T., Stern D. M. Interleukin-I induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc. Narl. Acad. Sci. 1986; 83: 3460–3464
   PubMed Web of Science ®Google Scholar
• Nawroth P. P., Stern D. M. Modulation of en-dothelical cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 1986; 163: 140–745
   Google Scholar
• Bevilacqua M., Pober J., Magear G., Fiers W., Cotran R., Cimbrone M. Recombinant human tissue necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with Interleukin-l. Proc. Natl. Acad. Sci. USA 1986; 83: 4533–4537
   PubMed Web of Science ®Google Scholar
• Clauss M., Cerlach M., Gerlach H., Brett J., Wang F., Familletti P. C., Pan Y. C. E., Connolly D. T., Stern D. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial and monocyte procoagulant activity and promotes monocyte migation. J. Exp. Med. 1990; 172: 1535–1545
   PubMed Web of Science ®Google Scholar
• Bevilacqua M. P., Schleef R. R., Gimbrone H. A., Lo-Shuktoff D. J. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin-l. J. Clin. Invest. 1986; 78: 587–591
   PubMed Web of Science ®Google Scholar
• Emeis J. J., Kooistra T. Interleukin-l and li-popolysaccharide induce an inhibitor of plasminogen activator in vivo and in cultured endothelial cells. J. Exp. Med. 1986; 163: 1260–1266
   PubMed Web of Science ®Google Scholar
• Nachman R. L., Hajjar K. A., Silverstein R. L., Di-Narello C. A. Interleukin-I induces endothelial cell synthesis of plasminogen activator inhibitor. J. Exp. Med. 1986; 163: 1595–1600
   PubMed Web of Science ®Google Scholar
• Moon D. K., Geczy C. L. Recombinant IFN-g synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J. Immunol. 1988; 141: 1536–1542
   PubMed Web of Science ®Google Scholar
• Carlsen E., Flatmark A., Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. Transplant 1988; 46: 575–580
   PubMed Web of Science ®Google Scholar
• Geczy C. L., Jones A. Procoagulant induction by human lymphokine and interferences/PMA on a myelo-monocytic cell line, RC22. Br. J. Haematol. 1988; 70: 211–218
   PubMed Web of Science ®Google Scholar
• Miyauchi S., Moroyama T., Kyoizumi S., Asakawa J., Okamoto T., Takada K. Malignant tumor cell lines produce interleukin-I-like factor. In Vitro Cell Dev. Biol. 1988; 24: 753–758
   PubMed Web of Science ®Google Scholar
• Noguchi M., Sakai T., Kisiel W. Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells. Biochem. Biophys. Res. Common. 1989; 160: 222–227
   PubMed Web of Science ®Google Scholar
• Myers T. J., Rickles F. R., Barb C., Cronlund M. Fibrinopeptide A in acute leukemia: Relationship of activation of blood coagulation to disease activity. Blood 1981; 57: 518–525
   PubMed Web of Science ®Google Scholar
• Bauer K. A., Rosenberg R. D. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 791–796
   PubMed Web of Science ®Google Scholar
• Abshire T. C., Gold S. H., Odom L. F., Carson S. D., Hathaway W. E. The coagulopathy of' childhood leukemia. Thrombin activation or primary fibrinolysis'?. Cancer 1990; 66: 716–721
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Edwards R. L., Barb C., Cronlund M. Abnormalities of blood coagulation in patients with cancer: Fibrinopeptide A generation and tumor growth. Cancer 1983; 51: 301–307
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Levine M., Edwards R. L. He-mostatic alterations in cancer patients. Ccncer Metastases Rev. 1992; 11: 237–248
   PubMed Web of Science ®Google Scholar
• Tabin C. J. Retinoids, homeoboxes. and growth factors: toward molecular models for limb development. Cell 1991; 66: 199–217
   PubMed Web of Science ®Google Scholar
• Sporn M. 9., Roberts A. 9. Role of retinoids in differentation and carcinogenesis. J. Natl. Cancer Inst. 1984; 73: 1381–1386
   PubMedGoogle Scholar
• Jetten A. M. Modulation of cell growth by retinoids and the possible mechanisms of action. Fed. Proc. 1984; 43: 134–139
   PubMedGoogle Scholar
• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Berger R., Fenaux P., Degos L. All-trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. l. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Frankel S. R., Miller W. H., Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M. S., Dimitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-reti-noic acid). N. Engl. J. Med. 1991; 374: 1385–1393
   Web of Science ®Google Scholar
• Chen Z., Xue Y., Zhang R., Taor R., Xia X., Li C., Wang W., Zu W., Yao X., Lino B. A clinical and experimental study of all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Petkovich J., Brand N., Krust A., Chambn P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–450
   PubMed Web of Science ®Google Scholar
• Brand N., Petkovich M., Krust A., Chambon P., De The H., Marchio A., Dejean A. Identification of a second human retinoic acid receptor. Nature 1988; 332: 850–853
   PubMed Web of Science ®Google Scholar
• Mattei M. G., Petkovich M., Mattei J. F., Brand N., Chambon P. Mapping of the human retinoic acid receptor to the 21 band of chromosome 17. Hum. Genet. 1988; 80: 186
   PubMed Web of Science ®Google Scholar
• De The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 558–561
   PubMed Web of Science ®Google Scholar
• Scrobohaci M. L., Dombret H., Ghorra P., Baurman H., Castaigne S., Daniel M. T., Boffa M. C., Amiral J., Degos L. Disseminated intravascular coagulation (DIC) and/or primary fibrinolysis in acute promyelocytic leukemia. Effect of all-trans retinoic acid. Blood 1991; 183, (abstr)
   Google Scholar
• Ishii H., Horie S., Kizaki K., Kazama M. Retinoic acid counteracts both the downregulation of throm-bomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 1992; 80: 2556–2562
   PubMed Web of Science ®Google Scholar
• Hirata F., Schiffman E., Venkatasubramanian K., Solomon D., Axelrod J. A. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocor-ticoids. Proc. Natl. Acad. Sci. USA 1980; 77: 2533–2536
   PubMed Web of Science ®Google Scholar
• Chang K. S., Wang G., Freireich E. J., Daly M., Nay-Lor S. C., Trujillo J. M., Stass S. A. Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 1992; 79: 1802–1810
   PubMed Web of Science ®Google Scholar
• Feldman E. J., Arlin Z. A., Ahmed T., Miltelman A., Ascensao J., Puccio C. A., Coombe N., Baskind P. Acute promyelocytic leukemia: A 5–year experience with new antileukemia agents and a new approach to preventing fatal hemorrhage. Acta Haemat. 1989; 82: 117–121
   PubMed Web of Science ®Google Scholar